Abstract
Background
Primary ovarian insufficiency (POI) can be seen in adolescents secondary to genetic or autoimmune conditions, or gonadotoxic therapies. Often times, its underlying cause is not identified. It is a rare condition in pediatrics, but a thorough evaluation is required for a timely diagnosis and optimizing outcomes.
Objectives
We aim to describe the clinical phenotype of idiopathic POI in an adolescent population seen in a referral center, and evaluate its diagnostic approach.
Methods
All patients evaluated between 2012 and 2018 were identified using the diagnostic codes for POI. Medical records were manually reviewed and clinical information was extracted. Cases were excluded from the final sample if they were found to have incomplete diagnostic information, Turner syndrome, eating disorders, gonadal surgeries and/or a history of oncological conditions or treatments.
Results
Forty-eight patients with POI were identified, and only seven met the established criteria. Anti-ovarian and anti-thyroid antibodies were evaluated in 100% and 86%, respectively, while only 29% were tested for anti-adrenal autoimmunity. The karyotype was obtained consistently, while the fragile X mental retardation 1 (FMR1) gene expansion was only assessed in approximately a third of the patients. Finally, only 29% of patients received reproductive counseling or referral to a fertility specialist.
Conclusions
Diagnostic evaluation for POI appears to be challenging to pediatric providers. Anti-ovarian antibodies are frequently obtained despite the lack of their clinical significance in POI, while anti-adrenal antibodies, which are the preferred diagnostic test, are not commonly obtained. Reproductive orientation or referral is seldom provided to the adolescent population.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Gordon CM, Kanaoka T, Nelson LM. Update on primary ovarian insufficiency in adolescents. Curr Opin Pediatr 2015;27:511–9.10.1097/MOP.0000000000000236Search in Google Scholar PubMed
2. Nelson LM. NIH public access. N Engl J Med 2009;360:606–14.10.1056/NEJMcp0808697Search in Google Scholar PubMed PubMed Central
3. ACOG. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014;124:193–7.10.1097/01.AOG.0000451757.51964.98Search in Google Scholar PubMed
4. Sadeghi MR. New hopes for the treatment of primary ovarian insufficiency/premature ovarian failure. J Reprod Infertil 2013;14:1–2.Search in Google Scholar PubMed
5. Al-Agha AE, Ahmed IA, Nuebel E, Moriwaki M, Moore B, et al. Primary ovarian insufficiency and azoospermia in carriers of a homozygous PSMC3IP stop gain mutation. J Clin Endocrinol Metab 2018;103:555–63.10.1210/jc.2017-01966Search in Google Scholar PubMed PubMed Central
6. Metzger ML, Meacham LR, Patterson B, Casillas JS, Constine LS, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013;31:1239–47.10.1200/JCO.2012.43.5511Search in Google Scholar PubMed PubMed Central
7. Gao J, Jiao X, Dang Y, Li J, Li G, et al. Identification of patients with primary ovarian insufficiency caused by autoimmunity. Reprod Biomed Online 2017;35:475–9.10.1016/j.rbmo.2017.06.010Search in Google Scholar PubMed
8. Szlendak-Sauer K, Jakubik D, Kunicki M, Skorska J, Smolarczyk R. Autoimmune polyglandular syndrome type 3 (APS-3) among patients with premature ovarian insufficiency (POI). Eur J Obstet Gynecol Reprod Biol 2016;203:61–5.10.1016/j.ejogrb.2016.05.023Search in Google Scholar PubMed
9. Pederson J, Kumar RB, Adams Hillard PJ, Bachrach LK. Primary ovarian insufficiency in adolescents: a case series. Int J Pediatr Endocrinol 2015;2015:13.10.1186/s13633-015-0009-zSearch in Google Scholar PubMed PubMed Central
10. Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013;25:375–81.10.1097/GCO.0b013e328364ed2aSearch in Google Scholar PubMed
11. Oktay K, Bedoschi G, Berkowitz K, Bronson R, Kashani B, et al. Fertility preservation in females with turner syndrome: a comprehensive review and practical guidelines. J Pediatr Adolesc Gynecol 2016;29:409–16.10.1016/j.jpag.2015.10.011Search in Google Scholar PubMed PubMed Central
12. Rivkees SA. Ending the late diagnosis of Turner syndrome through a novel high-throughput assay. Pediatr Endocrinol Rev 2012;9:698–700.Search in Google Scholar PubMed
13. Murdock DR, Donovan FX, Chandrasekharappa SC, Banks N, Bondy C, et al. Whole-Exome sequencing for diagnosis of turner syndrome: toward next-generation sequencing and newborn screening. J Clin Endocrinol Metab 2017;102:1529–37.10.1210/jc.2016-3414Search in Google Scholar PubMed
14. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991;67:1047–58.10.1016/0092-8674(91)90283-5Search in Google Scholar PubMed
15. Oostra B, Willemsen R. FMR1: a gene with three faces. Biochim Biophys Acta 2009;1790:467–77.10.1016/j.bbagen.2009.02.007Search in Google Scholar PubMed
16. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, et al. The FMR1 premutation and reproduction. Fertil Steril 2007;87:456–65.10.1016/j.fertnstert.2006.09.004Search in Google Scholar PubMed
17. Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 2006;14:253–5.10.1038/sj.ejhg.5201510Search in Google Scholar PubMed
18. Allen EG, Sullivan AK, Marcus M, Small C, Dominguez C, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007;28:2142–52.10.1093/humrep/dem148Search in Google Scholar
19. Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, et al. FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 2011;13:49–5.10.1097/GIM.0b013e3181fa9fadSearch in Google Scholar
20. Tassone F, Iong KP, Tong TH, Lo J, Gane LW, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012;4:100.10.1186/gm401Search in Google Scholar PubMed
21. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden JJ, Yang KT, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the international collaborative POF in fragile X study – preliminary data. Am J Med Genet 1999;83:322–5.10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-BSearch in Google Scholar PubMed
22. Hoyos LR, Thakur M. Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency. J Assist Reprod Genet 2017;34:315–23.10.1007/s10815-016-0854-6Search in Google Scholar PubMed
23. Komorowska B. Autoimmune premature ovarian failure. Prz Menopauzalny 2016;15:210–4.10.5114/pm.2016.65666Search in Google Scholar PubMed
24. La Marca A, Brozzetti A, Sighinolfi G, Marzotti S, Volpe A, et al. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol 2010;22:277–82.10.1097/GCO.0b013e32833b6c70Search in Google Scholar PubMed
25. Bakalov VK, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril 2005;84:958–65.10.1016/j.fertnstert.2005.04.060Search in Google Scholar PubMed
26. Reato G, Morlin L, Chen S, Furmaniak J, Rees Smith B, et al. Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab 2011;96:E1255–61.10.1210/jc.2011-0414Search in Google Scholar PubMed
27. Falorni A, Laureti S, Candeloro P, Perrino S, Coronella C, et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002;78:270–9.10.1016/S0015-0282(02)03205-3Search in Google Scholar PubMed
28. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107–34.10.1210/edrv.18.1.0291Search in Google Scholar PubMed
29. LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988;16:115–22.10.1111/j.1600-0897.1988.tb00180.xSearch in Google Scholar PubMed
30. Kanj RV, Ofei-Tenkorang NA, Altaye M, Gordon CM. Evaluation and management of primary ovarian insufficiency in adolescents and young adults. J Pediatr Adolesc Gynecol 2018;31:13–8.10.1016/j.jpag.2017.07.005Search in Google Scholar PubMed
31. Nahata L, Ziniel SI, Garvey KC, Yu RN, Cohen LE. Fertility and sexual function: a gap in training in pediatric endocrinology. J Pediatr Endocrinol Metab 2017;30:3–10.10.1515/jpem-2016-0044Search in Google Scholar PubMed
32. Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod 2015;30:608–15.10.1093/humrep/deu353Search in Google Scholar PubMed
33. Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol 2016;28:217–22.10.1097/GCO.0000000000000268Search in Google Scholar PubMed PubMed Central
© 2019 Walter de Gruyter GmbH, Berlin/Boston
